Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: LarryS who wrote (16455)	11/20/2003 1:05:08 AM
From: Bluegreen	Respond to of 17367

Larry, I have never heard of a company giving a drug for free for life just for being in a trial. For now, there is no cure for moderate to severe psoriasis. Raptiva as you know is THE ONLY biological approved for CHRONIC CONTINUOUS USE. The 75 soldiers set out by DNA will probably be pounding away at the fact that Raptiva has been in testing for YEARS around 3000 treated as a DERMATOLOGICAL biologic for moderate to severe psoriasis. Now just how long and how many patients were in the Enbrel for moderate to severe psoriasis trial????LOL Which one will Patients and DERMATOLOGICAL physicians choose???? Remember Dermatologists DON'T treat rheumatoid arthritis. DERMATOLOGISTS don't give a HOOT about Enbrel history with rheumatoid arthritis. They want a SAFE and EFFECTIVE med with LONG moderate to severe PSORIASIS trial history. THE LARGEST trial of ANY biologic for moderate to severe Psoriasis. NEJM FAILS to mentions the trial in which Raptiva had around 67 percent PASI 75 LONG TERM. Here is the link>>>>>>>>http://www.pslgroup.com/dg/237952.htm

To: LarryS who wrote (16455)	11/20/2003 1:15:17 AM
From: Bluegreen	Respond to of 17367

Larry, you might want to post this over and over again at the swamp......it is from the link I just provided. Slogan from DNA and Xoma should be.....You think you like the results now........You ain't seen NOTHING yet!!!!!!>>>>>>>Additionally, 21 months (84 weeks) of data from an open-label study evaluating the long-term safety and tolerability of continuous Raptiva will be presented. The 21-month data analysis results showed that 67 percent (130/194) of patients achieved a PASI 75 response with weekly Raptiva therapy. "These data further support the sustained and potentially increased clinical benefit of Raptiva when administered continuously for the treatment of moderate-to-severe plaque psoriasis," said Hal Barron M.D., F.A.C.C., Genentech's vice president, Medical Affairs.<<<<<<<<<<